<html>
<head>
<title>Utah Legislature HB0110</title>
</head>
<body>
<div id="content">
<font face="Arial">
</font><font face="Arial" size="3">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>CONTROLLED SUBSTANCE AMENDMENTS</b></font><font face="Arial" size="2"></center><br/>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>2017 GENERAL SESSION</center><br/>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center><br/>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3"><b>Chief Sponsor:  Paul Ray</b></font><font face="Arial" size="2"></center><br/>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3">Senate Sponsor:  </font><font face="Arial" size="2"></font><font face="Arial" size="3">____________</font><font face="Arial" size="2"></center><br/>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>LONG TITLE</b><br/>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>General Description:</b><br/>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill modifies the Utah Controlled Substances Act regarding Schedule I.<br/>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Highlighted Provisions:</b><br/>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill:<br/>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adds the substance<br/>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide that is also<br/>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;known as U-47700 or "pink" to the list of controlled substances under Schedule I.<br/>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Money Appropriated in this Bill:</b><br/>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Special Clauses:</b><br/>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill provides a special effective date.<br/>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Utah Code Sections Affected:</b><br/>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDS:<br/>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#58-37-4">58-37-4</a></b>, as last amended by Laws of Utah 2015, Chapter 258<br/>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br/>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b>58-37-4</b><a name="58-37-4"></a> is amended to read:<br/>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>58-37-4.</b>   <b>Schedules of controlled substances -- Schedules I through V -- Findings</b><br/>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>required -- Specific substances included in schedules.</b><br/>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)  There are established five schedules of controlled substances known as Schedules I,<br/><hr>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;II, III, IV, and V which consist of substances listed in this section.<br/>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)  Schedules I, II, III, IV, and V consist of the following drugs or other substances by<br/>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the official name, common or usual name, chemical name, or brand name designated:<br/>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  Schedule I:<br/>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any of the<br/>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and<br/>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific<br/>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chemical designation:<br/>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Acetyl-alpha-methylfentanyl<br/>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);<br/>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Acetylmethadol;<br/>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Allylprodine;<br/>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Alphacetylmethadol, except levo-alphacetylmethadol also known as<br/>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;<br/>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Alphameprodine;<br/>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Alphamethadol;<br/>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]<br/>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);<br/>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-<br/>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;piperidinyl]-N-phenylpropanamide);<br/>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Benzylpiperazine;<br/>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Benzethidine;<br/>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Betacetylmethadol;<br/>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-<br/>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;piperidinyl]-N-phenylpropanamide);<br/>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-<br/>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;<br/>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Betameprodine;<br/>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Betamethadol;<br/>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Betaprodine;<br/>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Clonitazene;<br/><hr>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Dextromoramide;<br/>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Diampromide;<br/>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Diethylthiambutene;<br/>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Difenoxin;<br/>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Dimenoxadol;<br/>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Dimepheptanol;<br/>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Dimethylthiambutene;<br/>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)  Dioxaphetyl butyrate;<br/>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Z)  Dipipanone;<br/>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Ethylmethylthiambutene;<br/>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BB)  Etonitazene;<br/>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CC)  Etoxeridine;<br/>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(DD)  Furethidine;<br/>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(EE)  Hydroxypethidine;<br/>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(FF)  Ketobemidone;<br/>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(GG)  Levomoramide;<br/>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(HH)  Levophenacylmorphan;<br/>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(II)  Morpheridine;<br/>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(JJ)  MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);<br/>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KK)  Noracymethadol;<br/>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(LL)  Norlevorphanol;<br/>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(MM)  Normethadone;<br/>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(NN)  Norpipanone;<br/>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(OO)  Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]<br/>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;propanamide;<br/>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(PP)  PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);<br/>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(QQ)  Phenadoxone;<br/>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(RR)  Phenampromide;<br/>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(SS)  Phenomorphan;<br/>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(TT)  Phenoperidine;<br/>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(UU)  Piritramide;<br/><hr>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VV)  Proheptazine;<br/>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(WW)  Properidine;<br/>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XX)  Propiram;<br/>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(YY)  Racemoramide;<br/>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ZZ)  Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;<br/>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AAA)  Tilidine;<br/>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BBB)  Trimeperidine;<br/>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CCC)  3-methylfentanyl, including the optical and geometric isomers<br/>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); [<strike>and</strike>]<br/>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(DDD)  3-methylthiofentanyl<br/>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)[<strike>.</strike>]<u>; and</u><br/>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(EEE)  3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known</u><br/>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>as U-47700.</u><br/>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any of the<br/>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following opium derivatives, their salts, isomers, and salts of isomers when the existence of the<br/>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;salts, isomers, and salts of isomers is possible within the specific chemical designation:<br/>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Acetorphine;<br/>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Acetyldihydrocodeine;<br/>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Benzylmorphine;<br/>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Codeine methylbromide;<br/>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Codeine-N-Oxide;<br/>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Cyprenorphine;<br/>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Desomorphine;<br/>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Dihydromorphine;<br/>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Drotebanol;<br/>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Etorphine (except hydrochloride salt);<br/>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Heroin;<br/>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Hydromorphinol;<br/>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Methyldesorphine;<br/>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Methylhydromorphine;<br/>120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Morphine methylbromide;<br/><hr>121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Morphine methylsulfonate;<br/>122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Morphine-N-Oxide;<br/>123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Myrophine;<br/>124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Nicocodeine;<br/>125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Nicomorphine;<br/>126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Normorphine;<br/>127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Pholcodine; and<br/>128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Thebacon.<br/>129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Unless specifically excepted or unless listed in another schedule, any material,<br/>130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following hallucinogenic<br/>131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substances, or which contains any of their salts, isomers, and salts of isomers when the<br/>132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;existence of the salts, isomers, and salts of isomers is possible within the specific chemical<br/>133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position,<br/>134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and geometric isomers:<br/>135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;<br/>136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&alpha;-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; &alpha;-ET; and AET;<br/>137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:<br/>138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4-bromo-2,5-dimethoxy-&alpha;-methylphenethylamine; 4-bromo-2,5-DMA;<br/>139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:<br/>140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;<br/>141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  2,5-dimethoxyamphetamine, some trade or other names:<br/>142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,5-dimethoxy-&alpha;-methylphenethylamine; 2,5-DMA;<br/>143&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;<br/>144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  4-methoxyamphetamine, some trade or other names:<br/>145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4-methoxy-&alpha;-methylphenethylamine; paramethoxyamphetamine, PMA;<br/>146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  5-methoxy-3,4-methylenedioxyamphetamine;<br/>147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:<br/>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4-methyl-2,5-dimethoxy-&alpha;-methylphenethylamine; "DOM"; and "STP";<br/>149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  3,4-methylenedioxy amphetamine;<br/>150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  3,4-methylenedioxymethamphetamine (MDMA);<br/>151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-<br/><hr>152&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;<br/>153&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  N-hydroxy-3,4-methylenedioxyamphetamine, also known as<br/>154&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;<br/>155&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  3,4,5-trimethoxy amphetamine;<br/>156&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Bufotenine, some trade and other names:<br/>157&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3-(&beta;-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,<br/>158&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;<br/>159&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;<br/>160&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Dimethyltryptamine, some trade or other names: DMT;<br/>161&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Ibogaine, some trade and other names:<br/>162&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7-Ethyl-6,6&beta;,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino<br/>163&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[5,4-b] indole; Tabernanthe iboga;<br/>164&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Lysergic acid diethylamide;<br/>165&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Marijuana;<br/>166&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Mescaline;<br/>167&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Parahexyl, some trade or other names:<br/>168&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;<br/>169&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Peyote, meaning all parts of the plant presently classified botanically as<br/>170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from<br/>171&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any part of such plant, and every compound, manufacture, salts, derivative, mixture, or<br/>172&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));<br/>173&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  N-ethyl-3-piperidyl benzilate;<br/>174&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  N-methyl-3-piperidyl benzilate;<br/>175&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)  Psilocybin;<br/>176&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Z)  Psilocyn;<br/>177&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis<br/>178&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis<br/>179&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,<br/>180&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their isomers with similar chemical structure and pharmacological activity to those<br/>181&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substances contained in the plant, such as the following: &Delta;1 cis or trans tetrahydrocannabinol,<br/>182&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their optical isomers &Delta;6 cis or trans tetrahydrocannabinol, and their optical isomers &Delta;3,4<br/><hr>183&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these<br/>184&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substances is not internationally standardized, compounds of these structures, regardless of<br/>185&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;numerical designation of atomic positions covered;<br/>186&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BB)  Ethylamine analog of phencyclidine, some trade or other names:<br/>187&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,<br/>188&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;<br/>189&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CC)  Pyrrolidine analog of phencyclidine, some trade or other names:<br/>190&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;<br/>191&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(DD)  Thiophene analog of phencyclidine, some trade or other names:<br/>192&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and<br/>193&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(EE)  1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.<br/>194&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material<br/>195&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>196&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a depressant effect on the central nervous system, including its salts, isomers, and salts<br/>197&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of isomers when the existence of the salts, isomers, and salts of isomers is possible within the<br/>198&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;specific chemical designation:<br/>199&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Mecloqualone; and<br/>200&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Methaqualone.<br/>201&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Any material, compound, mixture, or preparation containing any quantity of the<br/>202&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following substances having a stimulant effect on the central nervous system, including their<br/>203&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;salts, isomers, and salts of isomers:<br/>204&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or<br/>205&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4,5-dihydro-5-phenyl-2-oxazolamine;<br/>206&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,<br/>207&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;<br/>208&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Fenethylline;<br/>209&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Methcathinone, some other names: 2-(methylamino)-propiophenone;<br/>210&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;<br/>211&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;<br/>212&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of<br/>213&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;optical isomers;<br/><hr>214&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  (&#177;)cis-4-methylaminorex ((&#177;)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);<br/>215&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  N-ethylamphetamine; and<br/>216&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  N,N-dimethylamphetamine, also known as<br/>217&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.<br/>218&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  Any material, compound, mixture, or preparation which contains any quantity of<br/>219&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the following substances, including their optical isomers, salts, and salts of isomers, subject to<br/>220&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;temporary emergency scheduling:<br/>221&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and<br/>222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).<br/>223&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  Unless specifically excepted or unless listed in another schedule, any material,<br/>224&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate<br/>225&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.<br/>226&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  Schedule II:<br/>227&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any of the<br/>228&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following substances whether produced directly or indirectly by extraction from substances of<br/>229&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vegetable origin, or independently by means of chemical synthesis, or by a combination of<br/>230&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;extraction and chemical synthesis:<br/>231&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Opium and opiate, and any salt, compound, derivative, or preparation of opium or<br/>232&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,<br/>233&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their respective salts, but including:<br/>234&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Raw opium;<br/>235&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(II)  Opium extracts;<br/>236&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(III)  Opium fluid;<br/>237&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IV)  Powdered opium;<br/>238&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Granulated opium;<br/>239&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VI)  Tincture of opium;<br/>240&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VII)  Codeine;<br/>241&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VIII)  Ethylmorphine;<br/>242&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IX)  Etorphine hydrochloride;<br/>243&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Hydrocodone;<br/>244&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XI)  Hydromorphone;<br/><hr>245&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XII)  Metopon;<br/>246&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XIII)  Morphine;<br/>247&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XIV)  Oxycodone;<br/>248&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XV)  Oxymorphone; and<br/>249&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XVI)  Thebaine;<br/>250&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Any salt, compound, derivative, or preparation which is chemically equivalent or<br/>251&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these<br/>252&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substances may not include the isoquinoline alkaloids of opium;<br/>253&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Opium poppy and poppy straw;<br/>254&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and<br/>255&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any salt, compound, derivative, or preparation which is chemically equivalent or identical with<br/>256&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,<br/>257&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and salts of isomers and derivatives, whether derived from the coca plant or synthetically<br/>258&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;produced, except the substances may not include decocainized coca leaves or extraction of coca<br/>259&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;leaves, which extractions do not contain cocaine or ecgonine; and<br/>260&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Concentrate of poppy straw, which means the crude extract of poppy straw in either<br/>261&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.<br/>262&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any of the<br/>263&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and<br/>264&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific<br/>265&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chemical designation, except dextrorphan and levopropoxyphene:<br/>266&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Alfentanil;<br/>267&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Alphaprodine;<br/>268&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Anileridine;<br/>269&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Bezitramide;<br/>270&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Bulk dextropropoxyphene (nondosage forms);<br/>271&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Carfentanil;<br/>272&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Dihydrocodeine;<br/>273&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Diphenoxylate;<br/>274&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Fentanyl;<br/>275&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Isomethadone;<br/><hr>276&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,<br/>277&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;levomethadyl acetate, or LAAM;<br/>278&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Levomethorphan;<br/>279&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Levorphanol;<br/>280&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Metazocine;<br/>281&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Methadone;<br/>282&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;<br/>283&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic<br/>284&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acid;<br/>285&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Pethidine (meperidine);<br/>286&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;<br/>287&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;<br/>288&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;<br/>289&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Phenazocine;<br/>290&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Piminodine;<br/>291&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Racemethorphan;<br/>292&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)  Racemorphan;<br/>293&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Z)  Remifentanil; and<br/>294&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Sufentanil.<br/>295&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Unless specifically excepted or unless listed in another schedule, any material,<br/>296&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>297&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a stimulant effect on the central nervous system:<br/>298&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Amphetamine, its salts, optical isomers, and salts of its optical isomers;<br/>299&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Methamphetamine, its salts, isomers, and salts of its isomers;<br/>300&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Phenmetrazine and its salts; and<br/>301&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Methylphenidate.<br/>302&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material,<br/>303&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>304&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a depressant effect on the central nervous system, including its salts, isomers, and salts<br/>305&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of isomers when the existence of the salts, isomers, and salts of isomers is possible within the<br/>306&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;specific chemical designation:<br/><hr>307&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Amobarbital;<br/>308&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Glutethimide;<br/>309&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Pentobarbital;<br/>310&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Phencyclidine;<br/>311&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Phencyclidine immediate precursors: 1-phenylcyclohexylamine and<br/>312&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1-piperidinocyclohexanecarbonitrile (PCC); and<br/>313&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Secobarbital.<br/>314&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) (A)  Unless specifically excepted or unless listed in another schedule, any material,<br/>315&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of Phenylacetone.<br/>316&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Some of these substances may be known by trade or other names:<br/>317&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.<br/>318&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  Nabilone, another name for nabilone:<br/>319&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&#177;)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,<br/>320&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6-dimethyl-9H-dibenzo[b,d]pyran-9-one.<br/>321&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  Schedule III:<br/>322&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any material,<br/>323&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>324&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a stimulant effect on the central nervous system, including its salts, isomers whether<br/>325&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,<br/>326&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and salts of isomers is possible within the specific chemical designation:<br/>327&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Those compounds, mixtures, or preparations in dosage unit form containing any<br/>328&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were<br/>329&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the<br/>330&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Code of Federal Regulations, and any other drug of the quantitive composition shown in that<br/>331&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;list for those drugs or which is the same except that it contains a lesser quantity of controlled<br/>332&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substances;<br/>333&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Benzphetamine;<br/>334&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Chlorphentermine;<br/>335&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Clortermine; and<br/>336&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Phendimetrazine.<br/>337&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any material,<br/><hr>338&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>339&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a depressant effect on the central nervous system:<br/>340&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Any compound, mixture, or preparation containing amobarbital, secobarbital,<br/>341&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients<br/>342&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;which are not listed in any schedule;<br/>343&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Any suppository dosage form containing amobarbital, secobarbital, or<br/>344&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug<br/>345&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration for marketing only as a suppository;<br/>346&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Any substance which contains any quantity of a derivative of barbituric acid or any<br/>347&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;salt of any of them;<br/>348&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Chlorhexadol;<br/>349&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Buprenorphine;<br/>350&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Any drug product containing gamma hydroxybutyric acid, including its salts,<br/>351&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;isomers, and salts of isomers, for which an application is approved under the federal Food,<br/>352&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drug, and Cosmetic Act, Section 505;<br/>353&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:<br/>354&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#177; -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;<br/>355&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Lysergic acid;<br/>356&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Lysergic acid amide;<br/>357&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Methyprylon;<br/>358&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Sulfondiethylmethane;<br/>359&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Sulfonethylmethane;<br/>360&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Sulfonmethane; and<br/>361&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Tiletamine and zolazepam or any of their salts, some trade or other names for a<br/>362&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:<br/>363&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:<br/>364&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,<br/>365&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;flupyrazapon.<br/>366&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a<br/>367&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Food and Drug Administration approved drug product, some other names for dronabinol:<br/>368&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or<br/><hr>369&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(-)-delta-9-(trans)-tetrahydrocannabinol.<br/>370&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Nalorphine.<br/>371&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Unless specifically excepted or unless listed in another schedule, any material,<br/>372&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation containing limited quantities of any of the following<br/>373&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:<br/>374&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90<br/>375&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of<br/>376&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;opium;<br/>377&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90<br/>378&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized<br/>379&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;therapeutic amounts;<br/>380&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more<br/>381&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline<br/>382&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alkaloid of opium;<br/>383&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more<br/>384&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in<br/>385&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized therapeutic amounts;<br/>386&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90<br/>387&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized<br/>388&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;therapeutic amounts;<br/>389&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more<br/>390&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in<br/>391&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized therapeutic amounts;<br/>392&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not<br/>393&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in<br/>394&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized therapeutic amounts; and<br/>395&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with<br/>396&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;one or more active, non-narcotic ingredients in recognized therapeutic amounts.<br/>397&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  Unless specifically excepted or unless listed in another schedule, anabolic steroids<br/>398&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;including any of the following or any isomer, ester, salt, or derivative of the following that<br/>399&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promotes muscle growth:<br/><hr>400&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Boldenone;<br/>401&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Chlorotestosterone (4-chlortestosterone);<br/>402&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Clostebol;<br/>403&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Dehydrochlormethyltestosterone;<br/>404&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Dihydrotestosterone (4-dihydrotestosterone);<br/>405&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Drostanolone;<br/>406&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Ethylestrenol;<br/>407&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Fluoxymesterone;<br/>408&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Formebulone (formebolone);<br/>409&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Mesterolone;<br/>410&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Methandienone;<br/>411&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Methandranone;<br/>412&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Methandriol;<br/>413&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Methandrostenolone;<br/>414&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Methenolone;<br/>415&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Methyltestosterone;<br/>416&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Mibolerone;<br/>417&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Nandrolone;<br/>418&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Norethandrolone;<br/>419&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Oxandrolone;<br/>420&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Oxymesterone;<br/>421&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Oxymetholone;<br/>422&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Stanolone;<br/>423&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Stanozolol;<br/>424&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)  Testolactone;<br/>425&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Z)  Testosterone; and<br/>426&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Trenbolone.<br/>427&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  Anabolic steroids expressly intended for administration through implants to cattle<br/>428&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or other nonhuman species, and approved by the Secretary of Health and Human Services for<br/>429&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;use, may not be classified as a controlled substance.<br/>430&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)  Schedule IV:<br/><hr>431&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any material,<br/>432&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not<br/>433&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.<br/>434&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any material,<br/>435&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances,<br/>436&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and<br/>437&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;salts of isomers is possible within the specific chemical designation:<br/>438&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Alprazolam;<br/>439&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Barbital;<br/>440&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Bromazepam;<br/>441&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Butorphanol;<br/>442&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Camazepam;<br/>443&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Carisoprodol;<br/>444&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Chloral betaine;<br/>445&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Chloral hydrate;<br/>446&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Chlordiazepoxide;<br/>447&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Clobazam;<br/>448&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Clonazepam;<br/>449&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Clorazepate;<br/>450&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Clotiazepam;<br/>451&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Cloxazolam;<br/>452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Delorazepam;<br/>453&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Diazepam;<br/>454&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Dichloralphenazone;<br/>455&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Estazolam;<br/>456&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Ethchlorvynol;<br/>457&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Ethinamate;<br/>458&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Ethyl loflazepate;<br/>459&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Fludiazepam;<br/>460&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Flunitrazepam;<br/>461&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Flurazepam;<br/><hr>462&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)  Halazepam;<br/>463&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Z)  Haloxazolam;<br/>464&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Ketazolam;<br/>465&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BB)  Loprazolam;<br/>466&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CC)  Lorazepam;<br/>467&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(DD)  Lormetazepam;<br/>468&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(EE)  Mebutamate;<br/>469&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(FF)  Medazepam;<br/>470&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(GG)  Meprobamate;<br/>471&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(HH)  Methohexital;<br/>472&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(II)  Methylphenobarbital (mephobarbital);<br/>473&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(JJ)  Midazolam;<br/>474&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KK)  Nimetazepam;<br/>475&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(LL)  Nitrazepam;<br/>476&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(MM)  Nordiazepam;<br/>477&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(NN)  Oxazepam;<br/>478&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(OO)  Oxazolam;<br/>479&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(PP)  Paraldehyde;<br/>480&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(QQ)  Pentazocine;<br/>481&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(RR)  Petrichloral;<br/>482&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(SS)  Phenobarbital;<br/>483&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(TT)  Pinazepam;<br/>484&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(UU)  Prazepam;<br/>485&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VV)  Quazepam;<br/>486&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(WW)  Temazepam;<br/>487&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XX)  Tetrazepam;<br/>488&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(YY)  Triazolam;<br/>489&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ZZ)  Zaleplon; and<br/>490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AAA)  Zolpidem.<br/>491&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Any material, compound, mixture, or preparation of fenfluramine which contains<br/>492&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any quantity of the following substances, including its salts, isomers whether optical, position,<br/><hr>493&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of<br/>494&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;isomers is possible.<br/>495&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material,<br/>496&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances<br/>497&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;having a stimulant effect on the central nervous system, including its salts, isomers whether<br/>498&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,<br/>499&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;isomers, and salts of isomers is possible within the specific chemical designation:<br/>500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Cathine ((+)-norpseudoephedrine);<br/>501&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Diethylpropion;<br/>502&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Fencamfamine;<br/>503&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Fenproprex;<br/>504&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Mazindol;<br/>505&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Mefenorex;<br/>506&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Modafinil;<br/>507&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Pemoline, including organometallic complexes and chelates thereof;<br/>508&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Phentermine;<br/>509&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Pipradrol;<br/>510&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Sibutramine; and<br/>511&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  SPA ((-)-1-dimethylamino-1,2-diphenylethane).<br/>512&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Unless specifically excepted or unless listed in another schedule, any material,<br/>513&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of dextropropoxyphene<br/>514&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.<br/>515&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)  Schedule V: Any compound, mixture, or preparation containing any of the<br/>516&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous<br/>517&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in<br/>518&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal<br/>519&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;qualities other than those possessed by the narcotic drug alone:<br/>520&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;<br/>521&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100<br/>522&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grams;<br/>523&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100<br/><hr>524&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grams;<br/>525&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of<br/>526&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;atropine sulfate per dosage unit;<br/>527&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  not more than 100 milligrams of opium per 100 milliliters or per 100 grams;<br/>528&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  not more than 0.5 milligram of difenoxin and not less than 25 micrograms of<br/>529&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;atropine sulfate per dosage unit;<br/>530&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  unless specifically exempted or excluded or unless listed in another schedule, any<br/>531&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant<br/>532&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;effect on the central nervous system, including its salts, isomers, and salts of isomers; and<br/>533&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)  all forms of Tramadol.<br/>534&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.  <b>Effective date.</b><br/>535&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>If approved by two-thirds of all the members elected to each house, this bill takes effect</u><br/>536&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>upon approval by the governor, or the day following the constitutional time limit of Utah</u><br/>537&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,</u><br/>538&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the date of veto override.</u><br/><br/><hr style="width:90%; color: #333; text-align: right" /><br/><hr style="width:90%; color: #333; text-align: right" /><br/><br/><b>Legislative Review Note<br/>Office of Legislative Research and General Counsel</b>
</font>
</div>
</body>
</html>
